α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?

Drug Discovery Today

Volumn 14, Issue 17-18, 2009, Pages 822-836

  Paleari, Laura ^a   Cesario, Alfredo ^b,c   Fini, Massimo ^d   Russo, Patrizia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CDC San Raffaele Velletri ^*  (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; BUNGAROTOXIN RECEPTOR ANTAGONIST; CISPLATIN; ERABUTOXIN; METHOTREXATE; METHYLLYCACONITINE; NEUROTOXIN; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; CALCIUM; SNAKE VENOM;

APOPTOSIS; CANCER SUSCEPTIBILITY; DISEASE COURSE; EXPERIMENTAL STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; NONHUMAN; OBSERVATIONAL STUDY; PLEURA MESOTHELIOMA; PRECANCER; PROTEIN EXPRESSION; REVIEW; ALLOSTERISM; ANGIOGENESIS; BIOLOGICAL MODEL; CHEMICAL MODEL; CHEMICALLY INDUCED DISORDER; DRUG DELIVERY SYSTEM; DRUG EFFECT; EPITHELIUM CELL; GENETICS; INFLAMMATION; LUNG; MESOTHELIOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PLEURA TUMOR; TUMOR CELL LINE;

ALLOSTERIC REGULATION; CALCIUM; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; HUMANS; INFLAMMATION; LUNG; MESOTHELIOMA; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PLEURAL NEOPLASMS; RECEPTORS, NICOTINIC; SNAKE VENOMS;

EID: 69749083891     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.06.016     Document Type: Review

References (135)

1. Wistuba I.I. Genetics of preneoplasia: lessons from lung cancer. Curr. Mol. Med. 7 (2007) 3-14
2. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 353 (2005) 1591-1603
3. Palumbo C., et al. Molecular targets and targeted therapies for malignant mesothelioma. Curr. Med. Chem. 15 (2008) 855-867
4. Fennell D.A., et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat. Clin. Pract. Oncol. 5 (2008) 136-147
5. In: Travis W.D., et al. (Ed). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (2008), IARC Press, Lyon
6. Sun S., et al. Lung cancer in never smokers-a different disease. Nat. Rev. Cancer 7 (2007) 778-790
7. Amos C.I., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40 (2008) 616-622
8. Thorgeirsson T.E., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452 (2008) 638-642
9. Hung R.J., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452 (2008) 633-637
10. Weiss R.B., et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet. 4 (2008) e1000125
11. Bierut L.J., et al. Variants in nicotinic receptors and risk for nicotine dependence. PLoS Genet. 4 7 (2008) e1000125
12. Spitz M.R., et al. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J. Natl. Cancer Inst. 100 (2008) 1552-1556
13. Corringer P.J., et al. Nicotinic receptors at the amino acid level. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 431-458
14. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16 (1993) 403-443
15. Lukas R.J., et al. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 51 (1999) 397-401
16. Dani J.A., and Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 699-729
17. Changeux J.P., and Edelstein S.J. Allosteric receptors after 30 years. Neuron 21 (1998) 959-980
18. Chavez-Noriega L.E., et al. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharm. Exp. Ther. 280 (1997) 346
19. Wang F., et al. Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J. Biol. Chem. 271 (1996) 17656
20. Brejc K., et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411 (2001) 269-276
21. Celie P.H., et al. Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an alpha-conotoxin PnIA variant. Nat. Struct. Mol. Biol. 12 (2005) 582
22. Celie P.H., et al. Crystal structure of acetylcholine-binding protein from Bulinus truncatus reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors. J. Biol. Chem. 280 (2005) 26457
23. Lummis S.C., et al. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature 438 (2005) 248
24. Lee W.Y., and Sine S.M. Principal pathway coupling agonist binding to channel gating in nicotinic receptors. Nature 438 (2005) 243
25. Celie P.H., et al. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41 (2004) 907-914
26. Cashin A.L., et al. Using physical chemistry to differentiate nicotinic from cholinergic agonists at the nicotinic acetylcholine receptor. J. Am. Chem. Soc. 127 (2005) 350-356
27. Benowitz N.L. Basic cardiovascular research and its implications for the medicinal use of nicotine. J. Am. Coll. Cardiol. 41 (2003) 497-498
28. Czernin J., and Waldherr C. Cigarette smoking and coronary blood flow. Prog. Cardiovasc. Dis. 45 (2003) 395-404
29. Pickworth W.B., and Fant R.V. Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. Psychoneuroendocrinology 23 (1998) 131-141
30. Dani J.A., and de Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol. Biochem. Behav. 70 (2001) 439-446
31. Benowitz N.L. Cigarette smoking and nicotine addiction. Med. Clin. North Am. 76 (1992) 415-437
32. Buisson B., and Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol. Sci. 23 (2002) 130-136
33. Monod J., et al. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12 (1965) 88-118
34. Bertrand D., and Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Pharmacol. 74 (2007) 1155-1163
35. 2+ current through human neuronal α7 nicotinic acetylcholine receptors. Cell Calcium 34 (2003) 205-209
36. 2+ permeability of human heteromeric nAChRs expressed by transfection in human cells. Cell Calcium 32 (2002) 53-58
37. Gilbert D., et al. Local and global calcium signals associated with the opening of neuronal alpha7 nicotinic acetylcholine receptors. Cell Calcium 45 2 (2009) 198-207
38. 2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 35 (2004) 1-8
39. Wang H., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
40. de Jonge W.J., and Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br. J. Pharmacol. 151 (2007) 915-929
41. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat. Rev. Drug Discov. 4 (2005) 673-684
42. Maneckjee R., and Minna J.D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 3294-3298
43. Schuller H.M. Carbon dioxide potentiates the mitogenic effects of nicotine and its carcinogenic derivative, NNK, in normal and neoplastic neuroendocrine lung cells via stimulation of autocrine and protein kinase C-dependent mitogenic pathways. Neurotoxicology 15 (1994) 877-886
44. Gotti C., and Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 74 (2004) 363-396
45. Lindstrom J. Neuronal nicotinic acetylcholine receptors. Ion Channels 4 (1996) 377-450
46. Sharma G., and Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. J. Neurobiol. 53 (2002) 524-534
47. Lam D.C., et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res. 67 (2007) 4638-4647
48. Paleari L., et al. Role of α7-nicotinic acetylcholine receptor in human non small cell lung cancer proliferation. Cell. Prol. 41 (2008) 936-959
49. Racké K., and Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm. Pharmacol. Ther. 17 (2004) 181-198
50. Russo P., et al. Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr. Med. Chem. 13 (2006) 3493-3512
51. Olale F., et al. Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J. Pharmacol. Exp. Ther 283 (1997) 675-683
52. Buisson B., and Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J. Neurosci. 21 (2001) 1819-1829
53. Kawai H., and Berg D.K. Nicotinic acetylcholine receptors containing alpha 7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-regulated by chronic nicotine exposure. J. Neurochem. 78 (2001) 1367-1378
54. Roman J., et al. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. FASEB J. 18 (2004) 1436-1438
55. Wang Y., et al. Human bronchial epithelial and endothelial cells express alpha7 nicotinic acetylcholine receptors. Mol. Pharmacol. 60 (2001) 1201-1209
56. Tsai, J.R. et al. (2006) Mitogen-activated protein kinase pathway was significantly activated in human bronchial epithelial cells by nicotine DNA and cell biology. 25, 312-322
57. Maus A.D., et al. Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol. Pharmacol. 54 (1998) 779-788
58. Benowitz N.L. Clinical pharmacology of nicotine. Annu. Rev Med. 37 (1986) 21-32
59. Guo J., et al. Persistent nicotine treatment potentiates amplification of the dihydrofolate reductase gene in rat lung epithelial cells as a consequence of Ras activation. J. Biol. Chem. 280 (2005) 30422-30431
60. West K.A., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Invest. 111 (2003) 81-90
61. Dey R.D., et al. Morphology, histochemistry, and distribution of serotonin-containing cells in tracheal epithelium of adult rabbit. Anat. Rec. 199 (1981) 23-31
62. Scheuermann D.W. Morphology and cytochemistry of the endocrine epithelial system in the lung. Int. Rev. Cytol. 106 (1987) 35-88
63. Freitag A., et al. Adrenoceptor- and cholinoceptor-mediated mechanisms in the regulation of 5-hydroxytryptamine release from isolated tracheae of newborn rabbits. Br. J. Pharmacol. 119 (1996) 91-98
64. Jull B.A., et al. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J. Cancer Res. Clin. Oncol. 127 (2001) 707-717
65. Chen M.F., et al. Human fetal lung changes associated with maternal smoking during pregnancy. Pediatr. Pulmonol. 3 (1987) 51-58
66. Rehan V.K., et al. Mechanism of nicotine-induced pulmonary fibroblast transdifferentiation. Am. J. Physiol. Lung Cell Mol. Physiol. 289 (2005) 667-676
67. Torday J.S., et al. Biologic role of fetal lung fibroblast triglycerides as antioxidants. Pediatr. Res. 49 (2001) 843-849
68. Torday J.S., et al. Metabolism and fate of neutral lipids of fetal lung fibroblast origin. Biochim. Biophys. Acta 1254 (1995) 198-206
69. Torday J.S., et al. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro. Pediatr. Pathol. Mol. Med. 22 (2003) 189-207
70. Leslie K.O., et al. Alpha smooth muscle actin expression in developing and adult human lung. Differentiation 44 (1990) 143-149
71. Toti P., et al. Bronchopulmonary dysplasia of the premature baby: an immunohistochemical study. Pediatr. Pulmonol. 24 (1997) 22-28
72. Sekhon H.S., et al. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. Clin. Invest. 103 (1999) 637-647
73. Sekhon H.S., et al. Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am. J. Respir. Crit. Care Med. 164 (2001) 989-994
74. Sekhon H.S., et al. Maternal nicotine exposure upregulates collagen gene expression in fetal monkey lung. Association with alpha7 nicotinic acetylcholine receptors. Am. J. Respir. Cell Mol. Biol. 26 (2002) 31-41
75. Sekhon H.S., et al. Expression of lynx1 in developing lung and its modulation by prenatal nicotine exposure. Cell Tissue Res. 320 (2005) 287-297
76. Ding L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455 (2008) 1069-1075
77. Song P., et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 63 (2003) 214-221
78. Paleari L., et al. Inhibition of non-neuronal α7-nicotinic receptor reduces tumorigenicity in A549 NSCLC xenografts. Int. J. Cancer 125 1 (2009) 199-211
79. Dasgupta P., et al. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6332-6337
80. Dasgupta P., et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J. Clin. Invest. 116 (2006) 2208-2217
81. Xin M., et al. Nicotine inactivation of the proapoptotic function of Bax through phosphorilation. J. Biol. Chem. 280 (2005) 10781-10784
82. Jin Z., et al. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J. Biol. Chem. 279 (2004) 23837-23844
83. Heeschen C., et al. Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J. Am. Coll. Cardiol. 48 (2006) 2553-2560
84. Zhu B.Q., et al. Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell 4 (2003) 191-196
85. Gallowitsch-Puerta M., and Pavlov V.A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci. 80 (2007) 2325-2329
86. Rosas-Ballina M., et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11008-11013
87. Su X., et al. Activation of the alpha7 nAChR reduces acid-induced acute lung injury in mice and rats. Am. J. Respir. Cell Mol. Biol. 37 (2007) 186-192
88. Léna D., and Changeux J.P. Allosteric nicotinic receptors, human pathologies. J. Physiol. 92 (1998) 63-74
89. Tsetlin V.I., and Hucho F. Snake and snail toxins acting on nicotinic acetylcholine receptors: fundamental aspects and medical applications. FEBS Lett. 557 (2004) 9-13
90. Tsetlin V.I. Snake venom alpha-neurotoxins and other 'three-finger' proteins. Eur. J. Biochem. 264 (1999) 281-286
91. Servent D., and Ménez A. In: Massaro E.J. (Ed). Handbook of Neurotoxicology Vol. 1 (2001), Humana Press Inc., Totowa, NJ 385-425
92. Nirthanan S., and Gwee M.C. Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on. J. Pharmacol. Sci. 94 (2004) 1-17
93. Kini R.M. Molecular moulds with multiple missions: functional sites in three-finger toxins. Clin. Exp. Pharmacol. Physiol. 29 (2002) 815-822
94. Fruchart-Gaillard C., et al. Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3216-3221
95. Antil-Delbeke S., et al. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor. J. Biol. Chem. 275 (2000) 29594-29601
96. Michalet S., et al. Relative spatial position of a snake neurotoxin and the reduced disulfide bond alpha (Cys192-Cys193) at the alpha gamma interface of the nicotinic acetylcholine receptor. J. Biol. Chem. 275 (2000) 25608-25615
97. Carlisle D.L., et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm. Pharmacol. Ther. 20 (2007) 629-641
98. Takacs Z., et al. Cobra (Naja spp.) nicotinic acetylcholine receptor exhibits resistance to Erabu sea snake (Laticauda semifasciata) short-chain alpha-neurotoxin. J. Mol. Evol. 58 (2004) 516-526
99. Sher E., et al. Peptide neurotoxins, small cell-lung carcinoma and neurological paraneoplastic syndromes. Biochimie 82 (2000) 927-936
100. Pillet L., et al. Genetic engineering of snake toxins. Role of invariant residues in the structural and functional properties of a curaremimetic toxin, as probed by site-directed mutagenesis. J. Biol. Chem. 268 (1993) 909-916
101. Endo T., and Tamiya N. Structure-function relationships of postsynaptic neurotoxins from snake venoms. In: Harvey A.L. (Ed). Snake Toxins (1991), Pergamon Press Inc., New York 165-222
102. Taylor P., et al. Toxins as probes for structure and specificity of synaptic target proteins. In: Ménez A. (Ed). Perspectives in Molecular Toxicology (2002), John Wiley & Sons, Chichester, UK 271-280
103. Ménez A., et al. In: Ménez A. (Ed). Perspectives in Molecular Toxicology Vol. 10 (2002), John Wiley & Sons, Ltd., Chichester 175-202
104. Bourne Y., et al. Crystal structure of α Cbtx-AChBP complex reveals essential interactions between snake α-neurotoxins and nicotinic receptors. EMBO J. 24 (2005) 1512-1522
105. Yi M., et al. Spontaneous conformational change and toxin binding in alpha7 acetylcholine receptor: insight into channel activation and inhibition. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8280-8285
106. Fruchart-Gaillard C., et al. How three-finger-fold toxins interact with various cholinergic receptors. J. Mol. Neurosci. 30 (2006) 7-8
107. Hogg R.C., et al. α-Conotoxins PnIA and [A10L] PnIA stabilize different states of the α7-L247T nicotinic acetylcholine receptor. J. Biol. Chem. 278 (2003) 26908-26914
108. Dutertre S., and Lewis R.J. Toxin insights into nicotinic acetylcholine receptors. Biochem. Pharmacol. 72 (2006) 661-670
109. Trombino S., et al. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res. 64 (2004) 135-145 [Erratum: Cancer Res. 64, 1559]
110. Trombino S., et al. Role of the non-neuronal human cholinergic system in lung cancer and mesothelioma: possibility of new therapeutic strategies. Curr. Med. Chem. - Anticancer Agents 4 (2004) 535-542
111. Catassi A., et al. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat. Res. Rev. 659 3 (2008) 221-231
112. Grozio A., et al. Nicotine, lung and cancer. Anticancer Agents Med. Chem. 7 (2007) 461-466
113. Grozio A., et al. Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int. J. Cancer 122 (2008) 1911-1915
114. Catassi A., et al. α-Cobratoxin, a natural (7-nicotinic receptor antagonist, as putative anticancer drug in non small cell lung cancer and mesothelioma. In: Goudey-Perrière, et al. (Ed). Toxines and Cancer (2006), Lavoisier 99-106
115. Catassi A., et al. α7-Cobratoxin as a nicotinic receptor-targeted drug for pleural mesothelioma. Eur. J. Cancer 44 (2008) 2296-2311
116. Paleari L., et al. Inhibition of non-neuronal α7-nicotinic receptor as anticancer treatment for human NSCLC. Am. J. Resp. Crit. Care Med. 179 (2009) 1141-1150
117. Russo, P. et al. (in press) Neuronal Cholinergic Toxines: possible drugs for lung cancer treatment. In Toxines et fonctions cholinergiques neuronales et non neuronales (Goudey-Perrière et al., eds). Lavoisier, pp. 63-67
118. Stevens K.E., et al. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15 (1996) 152-162
119. 2+-channels in human small cell lung carcinoma by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Int. J. Oncol. 16 (2000) 513-518
120. Cattaneo M.G., et al. Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma. Cancer. Res. 53 (1993) 5566-5568
121. Nelson M.E., et al. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol. Pharmacol. 63 (2003) 332-341
122. Quik M., et al. α-Bungarotoxin blocks the nicotinic receptor mediated increase in cell number in a neuroendocrine cell line. Brain Res. 655 (1994) 161-167
123. Tsuneki H., et al. Novel G423S mutation of human alpha7 nicotinic receptor promotes agonist-induced desensitization by a protein kinase C-dependent mechanism. Mol. Pharmacol. 71 (2007) 777-786
124. De Luca V., et al. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr. Scand. 114 (2006) 211-215
125. Leonard S., and Freedman R. Genetics of chromosome 15q13-q14 in schizophrenia. Biol. Psychiatry 60 (2006) 115-122
126. Severance E.G., et al. The alpha7 nicotinic acetylcholine receptor subunit exists in two isoforms that contribute to functional ligand-gated ion channels. Mol. Pharmacol. 66 (2004) 420-429
127. Selinger H., et al. New results with cobratoxin in caner therapy. Med. Welt. 20 (1951) 638
128. Calmette A., et al. Effetts du venim de cobra sur les greffles cancéreuses et sur le cancer spontané (adéno-carcinome) de la souris. C. R. Acad. Sci. (1933) 197-205
129. Lewis R.J., and Garcia M.L. Therapeutic potential of venom peptides. Nat. Drug Discov. 2 (2003) 791-802
130. Proskocil B.J., et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology 145 (2004) 2498-2506
131. Arredondo J., et al. The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells. J. Cancer Res. Clin. Oncol. 132 (2006) 653-663
132. Tsurutani J., et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogen 26 (2005) 1182-1195
133. Plummer III H.K., et al. Expression of the alpha-7 nicotinic acetylcholine receptor in human lung cells. Respir. Res. 6 (2005) 29
134. Chini B., et al. Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic subunit gene are expressed in neuronal and nonneuronal human cell lines. Proc. Natl. Acad. Sci. USA 89 5 (1992) 1572-1576
135. Zhang Q., et al. Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor mediated signaling pathways. Clin. Cancer Res. 13 (2007) 4686-4694